Adverse Events—Clinical
| Adverse event | Any time | ≤1 wk | >1 wk | Grade 3 or 4 |
| Nausea | 74% (28) | 71% (27) | 34% (13) | 8% (3) |
| Abdominal pain | 71% (27) | 68% (26) | 47% (18) | 18% (7) |
| Fatigue | 66% (25) | 26% (10) | 61% (23) | 3% (1) |
| Vomiting | 66% (25) | 58% (22) | 18% (7) | 3% (1) |
| Back pain | 34% (13) | 24% (9) | 11% (4) | 0 |
| Anorexia | 26% (10) | 13% (5) | 21% (8) | 0 |
| Edema limbs | 18% (7) | 0 | 18% (7) | 0 |
| Fever | 18% (7) | 11% (4) | 11% (4) | 0 |
| Constipation | 16% (6) | 5% (2) | 11% (4) | 0 |
| Dizziness | 16% (6) | 11% (4) | 11% (4) | 0 |
| Allergic reaction | 13% (5) | 13% (5) | 5% (2) | 0 |
| Arthralgia | 13% (5) | 3% (1) | 11% (4) | 0 |
| Dyspnea | 13% (5) | 0 | 13% (5) | 0 |
| Shoulder pain | 13% (5) | 5% (2) | 11% (4) | 0 |
| Ascites | 11% (4) | 0 | 11% (4) | 3% (1) |
| Chills | 11% (4) | 0 | 11% (4) | 0 |
| Dysgeusia | 11% (4) | 3% (1) | 11% (4) | 0 |
| Gastric stenosis | 3% (1) | 0 | 3% (1) | 3% (1) |
| Hepatic failure* | 3% (1) | 0 | 3% (1) | 3% (1) |
| Liver abscesses | 3% (1) | 0 | 3% (1) | 3% (1) |
| Paroxysmal atrial tachycardia | 3% (1) | 0 | 3% (1) | 3% (1) |
| Thoracic pain | 3% (1) | 3% (1) | 3% (1) | 3% (1) |
| Upper gastrointestinal hemorrhage | 3% (1) | 0 | 3% (1) | 3% (1) |
↵* We suspected mix of disease progression and radioembolization induced liver disease. This patient is also included in parameter “ascites.”
Numbers of events are in parentheses. Adverse events are those with incidence of >10% or CTCAE grade 3 or 4, after treatment, regardless of relation with 166Ho radioembolization.